Beneke M., Kuemmel B., Roed I., Spechtmeyer H. (1988) Treatment of anxiety neurosis with ipsapirone. Psychopharmacology (Suppl.) 96: 353
2.
Blier P., de Montigny C., Chaput Y. (1987) Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression . J Clin Psychopharmacol7: 245-355
3.
Bohm C., Placchi M., Stallone F., Gammans R.E., Alms D.R., Shrotriya R.C., Robinson D.S. (1990a) A double-blind comparison of buspirone, clobazam, and placebo in patients with anxiety treated in a general practice setting . J Clin Psychopharmacol10: 385-425
4.
Bohm C., Robinson D.S., Gammans R.E., Shrotriya R.C., Alms D.R., Leroy A., Placchi M. (1990b) Buspirone therapy in anxious elderly patients: a controlled clinical trial. J Clin Psychopharmacol10: 475-515
5.
Borison R.L., Albrecht J.W., Diamond B.I. (1990) Efficacy and safety of a putative anxiolytic agent: ipsapirone. Drug Literature26: 207-210
6.
Deakin J F W, Graeff F.G. (1991) 5-HT and mechanisms of defence. J Psychopharmacol5: 305-315
7.
Deakin J F W, Pennell I., Upadhyaya A.K., Lofthouse R. (1990) A neuroendocrine study of 5HT function in depression: evidence for biological mechanisms of endogenous and psychosocial causation . Psychopharmacology4: 357-360
8.
Delgado P.L., Charney D.S., Price L.H., Aghajanian G.K., Landis H., Heninger G.R. (1990) Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatr47: 411-418
9.
Den Boer J.A., Westenberg H G M (1990) Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology102: 85-94
10.
Eison A.S., Yocca F.D. (1985) Reduction in cortical 5HT2 receptor sensitivity after continuous gepirone treatment. Eur J Pharmacol11: 389-392
11.
Fabre L.F. (1990) Buspirone in the management of major depression: a placebo-controlled comparison. J Clin Psychiatr51: 555-615
12.
Friston K.J., Grasby P.M., Frith C.D., Bench C.J., Dolan R.J., Cowen P.J., Liddle P.F., Frackowiak R S J (1991) The neurotransmitter basis of cognition: psychopharmacological activation studies using positron emission tomography. In Chadwick D J, Whelan J (eds), Exploring brain functional anatomy with positron tomography (Ciba Foundation Symposium 163)Wiley, Chichester, pp. 76-92
13.
Goldberg T., Rath M., Traber J., Zilles K., Schleicher A. (1985) An autoradiographic identification and topographical analysis of high affinity serotonin receptor subtypes as a target for the novel putative anxiolytic TV X Q 7821. Brain Res358: 129-136
14.
Goldberg H.L., Finnerty R.J. (1979) The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatr136: 1184-1187
15.
Hallstrom C., Cox J. ( 1991) Rapid response to buspirone: assessment in a general practice setting. Br J Clin Res2: 65-80
16.
Heller A.H., Beneke M., Kuemmel B., Spencer D., Kurtz N.M. (1990) Ipsapirone: evidence for efficacy in depression . Drug Literature26: 219-222
17.
Jenike M.A., Baer L., Buttolph L. (1991) Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. J Clin Psychiatr52: 13-14
18.
Jenkins S.W., Robinson D.S., Fabre L.F. Jr, Andary J.J., Messina M.E., Reich L.A. (1990) Gepirone in the treatment of major depression. J Clin Psychopharmacol10: 77S-85S
19.
Johnstone E.C., Owens D G C, Frith C.D., McPherson K., Dowie C., Riley G., Gold A. ( 1986) Neurotic illness and its responses to anxiolytic and antidepressant treatment. Psychol Med10: 321-328
20.
Kahn R.J., MacNair D M, Lipman R.S., Covi L., Rickels K., Downing R., Fisher S., Frankenthaler L.M. (1986) Imipramine and chlordiazepoxide in depressive and anxiety disorders. II Efficacy in anxious outpatients. Arch Gen Psychiatr43: 79-85
21.
Kennett G.A., Dickinson S., Curzon G. (1985) Enhancement of some 5HT-dependent behavioural responses following repeated immobilization in rats. Brain Res330: 253-263
22.
Kuemmel B., Beneke M., Schoellnhammer G., Spechtmeyer H. (1988) Ipsapirone in the treatment of generalized anxiety disorder. Psychopharmacology (Suppl.) 96: 353
23.
Markovitz P.J., Stagno S.J., Calabrese J.R. (1990) Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. Am J Psychiatr147: 798-800
24.
McEntee W.J., Crook T.H. (1991) Serotonin, memory and the aging brain. Psychopharmacology103: 143-149
25.
Martin P., Puech A.J. (1990) Effects of buspirone, gepirone, ipsapirone and their common metabolite 1-PP in the learned helplessness paradigm. Psychopharmacology101: S36
26.
Murphy S.M., Owen R., Tyrer P. (1989) Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks' treatment with diazepam or buspirone. Br J Psychiatr154: 529-534
27.
Pato M.T., Pigott T.A., Hill J.L., Grover G.N., Bernstein S., Murphy D.L. (1991) Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatr148: 127-129
28.
Pecknold J.C., Familamiri P., Chang H., Wilson R., Alarcia J., McClure D.J. (1985) Buspirone: anxiolytic? Prog Neuro-Psychopharmacol Biol Psychiatr9: 639-642
29.
Pohl R., Balon R., Yeragani V.K., Gershon S. (1989) Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology (Suppl. 1): 60-67
30.
Rickels K., Weisman K., Norstad N. (1982) Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatr43: 81-86
31.
Rickels K., Schweizer E., Csanalosi I. (1988) Long-term treatment of anxiety and risk of withdrawal . Arch Gen Psychiatr45: 444-450
32.
Robinson D.S., Shrotriya R.C., Alms D.R., Messina M., Andary J. (1989) Treatment of panic disorder: non-benzodiazepine anxiolytics, including buspirone. Psychopharmacol Bull25: 21-26
33.
Robinson D.S., Rickels K., Feighner J., Fabre L.F., Gammans R.E., Shrotriya R.C., Alms D.R., Andary J.J., Messina M.E. (1990) Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression . J Clin Psychopharmacol10: 67S-76S
34.
Rowan M.J., Cullen W.K., Moulton B. (1990) Buspirone impairment of performance of passive avoidance and spatial learning tasks in the rat. Psychopharmacology100: 393-398
35.
Sanger M.J., Jolly D. (1990) Performance of a passive avoidance response is disrupted by compounds acting at 5HT1A receptors. Behav Pharmacol1: 235-240
36.
Schweizer E., Rickels K., Lucki I. (1986) Resistance to the anti-anxiety effects of buspirone in patients with a history of benzodiazepine use. New Engl J Med314: 719-720
37.
Sheehan D.V., Raj A.B., Sheehan K.H., Soto S. ( 1990) Is buspirone effective for panic disorder? J Clin Psychopharmacol10: 3-11
38.
Upadhyaya A.K., Pennell I., Cowen P.J., Deakin J F W (1991) Blunted growth hormone and prolactin responses to L-tryptophan in depression; a state-dependent abnormality. J Affective Disord21 : 213-218
39.
Westenberg H G M, van Vliet I.M., Den Boer J.A. (1992) Flesinoxan, a selective 5-HT1A agonist, in the treatment of panic disorder. Clin Neuropharmacol15(1B): 60B
